Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy

Histone methyltransferase SETD2 plays a critical role in maintaining genomic integrity and stability. Here, we investigated the characteristics of SETD2 somatic mutation in the cancer genome atlas pan-cancer cohort. Our data revealed that, compared with SETD2 nonmutant patients, SETD2 mutant patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Mingdong, Zhao, Bin, Liu, Mengshan, Wu, Le, Li, Yingying, Zhai, Yingna, Shen, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203790/
https://www.ncbi.nlm.nih.gov/pubmed/34127768
http://dx.doi.org/10.1038/s41698-021-00193-0
_version_ 1783708242883379200
author Lu, Mingdong
Zhao, Bin
Liu, Mengshan
Wu, Le
Li, Yingying
Zhai, Yingna
Shen, Xian
author_facet Lu, Mingdong
Zhao, Bin
Liu, Mengshan
Wu, Le
Li, Yingying
Zhai, Yingna
Shen, Xian
author_sort Lu, Mingdong
collection PubMed
description Histone methyltransferase SETD2 plays a critical role in maintaining genomic integrity and stability. Here, we investigated the characteristics of SETD2 somatic mutation in the cancer genome atlas pan-cancer cohort. Our data revealed that, compared with SETD2 nonmutant patients, SETD2 mutant patients had higher tumor mutation burden and microsatellite instability. In addition, the transcriptions of most genes related to immune activities were upregulated in patients with SETD2 mutant tumors. Further examination of cancer patients treated with immune checkpoint inhibitors suggested SETD2 mutation was associated with favorable clinical outcomes. These results have implication for the personalization of cancer immunotherapy.
format Online
Article
Text
id pubmed-8203790
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82037902021-07-01 Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy Lu, Mingdong Zhao, Bin Liu, Mengshan Wu, Le Li, Yingying Zhai, Yingna Shen, Xian NPJ Precis Oncol Brief Communication Histone methyltransferase SETD2 plays a critical role in maintaining genomic integrity and stability. Here, we investigated the characteristics of SETD2 somatic mutation in the cancer genome atlas pan-cancer cohort. Our data revealed that, compared with SETD2 nonmutant patients, SETD2 mutant patients had higher tumor mutation burden and microsatellite instability. In addition, the transcriptions of most genes related to immune activities were upregulated in patients with SETD2 mutant tumors. Further examination of cancer patients treated with immune checkpoint inhibitors suggested SETD2 mutation was associated with favorable clinical outcomes. These results have implication for the personalization of cancer immunotherapy. Nature Publishing Group UK 2021-06-14 /pmc/articles/PMC8203790/ /pubmed/34127768 http://dx.doi.org/10.1038/s41698-021-00193-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Lu, Mingdong
Zhao, Bin
Liu, Mengshan
Wu, Le
Li, Yingying
Zhai, Yingna
Shen, Xian
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title_full Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title_fullStr Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title_full_unstemmed Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title_short Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
title_sort pan-cancer analysis of setd2 mutation and its association with the efficacy of immunotherapy
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203790/
https://www.ncbi.nlm.nih.gov/pubmed/34127768
http://dx.doi.org/10.1038/s41698-021-00193-0
work_keys_str_mv AT lumingdong pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT zhaobin pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT liumengshan pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT wule pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT liyingying pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT zhaiyingna pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy
AT shenxian pancanceranalysisofsetd2mutationanditsassociationwiththeefficacyofimmunotherapy

Ejemplares similares